Dynavax Technolo Stock Price, News & Analysis

Dynavax Technologies Corporation (Nasdaq: DVAX) reported strong financial results for Q3 2021, achieving total revenue of $108.3 million, driven by substantial growth in its HEPLISAV-B vaccine and CpG 1018 adjuvant. Revenue for HEPLISAV-B rose to $22.7 million, up from $11.6 million year-over-year, with market share increasing to 33.5%. CpG 1018 revenue soared to $84.3 million, up from $1.7 million in Q3 2020. Net loss widened to $28.4 million, reflecting a significant non-cash loss related to warrant liability. The company ended the quarter with $414.2 million in cash and equivalents.

On November 2, 2021, Dynavax Technologies Corporation (DVAX) announced the granting of nonstatutory stock options for 5,000 shares to a newly hired employee. The options, granted at an exercise price of $20.56 per share, equal the stock's closing price on the grant date. Each option has a 7-year term and vests over three years. This grant adheres to Nasdaq Listing Rule 5635(c)(4) and is part of Dynavax's 2021 Inducement Award Plan aimed at incentivizing new hires.

Dynavax Technologies Corporation (Nasdaq: DVAX) has appointed Scott Myers as a new member and Chairman of its Board of Directors, succeeding Dr. Andrew Hack. Myers brings nearly three decades of experience in the pharmaceutical and medical technology sectors. Under his leadership, Dynavax aims to enhance growth, focusing on its key products: HEPLISAV-B and CpG 1018. Dr. Hack remains on the board, providing continued guidance. This leadership change is expected to strengthen the company's strategic direction in vaccine development.

Dynavax Technologies Corporation (Nasdaq: DVAX) will report its third quarter 2021 financial results on November 4, 2021, after market close. The company will host a conference call and live audio webcast on the same day at 4:30 p.m. ET. Interested parties can access the webcast via the company’s investors' section. Dynavax is known for developing HEPLISAV-B, a hepatitis B vaccine, and is advancing its CpG 1018 adjuvant through research collaborations targeting vaccines for various diseases.

Dynavax Technologies Corporation (Nasdaq: DVAX) announced the granting of nonstatutory stock options for 115,000 shares to a new employee, effective October 18, 2021. The options have an exercise price of $17.14, aligned with the stock's closing price on the grant date. These options have a 7-year term and vest over three years, with one-third vesting after one year and the remainder in monthly installments. This grant adheres to Nasdaq Listing Rule 5635(c)(4) and follows their 2021 Inducement Award Plan for new hires.

Dynavax Technologies Corporation (Nasdaq: DVAX) announced positive topline results from Valneva's Phase 3 trial of the inactivated COVID-19 vaccine candidate, VLA2001, which utilizes Dynavax's CpG 1018 adjuvant. The trial met co-primary endpoints, demonstrating superiority over AstraZeneca's AZD1222 in geometric mean titers of neutralization antibodies and non-inferiority in seroconversion rates among adults aged 30 and older. VLA2001 showed a favorable tolerability profile with significantly fewer adverse events compared to AZD1222. Dynavax supports Valneva's continued development of the vaccine.

Dynavax Technologies Corporation (Nasdaq: DVAX) has secured a $22 million agreement with the U.S. Department of Defense to develop a recombinant plague vaccine using its CpG 1018 adjuvant over two and a half years. This collaboration includes a planned Phase 2 clinical trial, expected to commence in 2022, to assess the vaccine's immunogenicity, safety, and tolerability for adults aged 18 to 55 years. The initiative aims to enhance vaccine effectiveness and could lead to future commercial agreements with the U.S. government.

On October 1, 2021, Dynavax Technologies Corporation (Nasdaq: DVAX) announced the grant of 40,000 nonstatutory stock options to a newly-hired employee as part of their inducement for joining the company. The options are priced at $16.84 per share, equal to the stock's closing price on the grant date. They have a seven-year term, vesting over three years, with one-third vesting after one year and the remainder vesting monthly. This grant complies with Nasdaq Listing Rule 5635(c)(4) and is part of Dynavax's 2021 Inducement Award Plan.

Dynavax Technologies Corporation (Nasdaq: DVAX) will participate in several upcoming investor conferences, showcasing its commitment to vaccine development. Key presentations include the 2021 Cantor Virtual Global Healthcare Conference on September 30 at 12:00 p.m. E.T., the Guggenheim 2nd Annual Vaccine and Infectious Disease Conference on October 5 at 12:00 p.m. E.T., and the H.C. Wainwright 2nd Hepatitis B Virus Virtual Conference on October 13 at 12:00 p.m. E.T.. All events will be available via live webcast on their website's 'Events & Presentations' page.